An advanced collagen-based structural dermal filler, Evolence, is all set to enter the aesthetic market by the second half of 2008 following the FDA approval for its use in the correction of moderate to deep facial wrinkles and folds. The best thing about this dermal filler is that it does not require a pre-test and delivers immediate results. The Aesthetics Group of OrthoNeutrogena, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will look after the marketing of this product in the United States.

Highlights of Evolence
a. This product is developed using Glymatrix Technology.
b. It is meant for use in the correction of moderate to deep facial wrinkles and folds like nasolabial folds.
c. It is injected in the mid-to-deep dermis.
d. It contains naturally sourced collagen.
e. It replaces the body's lost collagen, adds volume and structural support in depleted areas and gives a person a naturally youthful appearance.
f. There is no requirement for any pre-tests.
g. The results are longer lasting and more durable than other collagen dermal fillers.
h. Results are immediately visible.
i. There is minimal bruising or swelling.
j. Clinical studies have shown that the results last for about six months.
k. Additional data for 12-month duration approval is being filed with the FDA.